SA
OTLK icon

Sanctuary Advisors’s Outlook Therapeutics OTLK Stock Holding History

Sanctuary Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,495
Closed -$35.5K – 2537
2025
Q3 		$35.5K Sell
33,495
-2,791
-8% -$4.83K ﹤0.01% 2395
2025
Q2 		$58.1K Buy
+36,286
New +$57.8K ﹤0.01% 2306

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanctuary Advisors's OTLK Position: Q4 2025 in Review

Sanctuary Advisors sold out of Outlook Therapeutics (OTLK) in Q4 2025, closing a stake of 33,495 shares — an estimated $35.5K sold.

Sanctuary Advisors first reported a position in OTLK in Q2 2025 and held it in 2 quarters. The position peaked at $58.1K in Q2 2025. 53 funds tracked by Wall St. Rank hold OTLK as of Q4 2025.

  • Sanctuary Advisors reported no remaining Outlook Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sanctuary Advisors sold 33,495 Outlook Therapeutics shares in Q4 2025, an estimated $35.5K.
  • Sanctuary Advisors first reported a position in Outlook Therapeutics in Q2 2025 and held it in 2 quarters.
  • Sanctuary Advisors's Outlook Therapeutics position peaked at $58.1K in Q2 2025.
  • 53 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2025.

Based on Sanctuary Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.